Introduction to the UroLift® System

The UroLift® System uses a different approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way so it no longer blocks the urethra.

It is transurethral BPH treatment that does not require ongoing medication, heating, cutting or removal of the prostate tissue.

Treatment with the UroLift® System does not preclude future UroLift® System treatments, TURP, or laser procedures.

Download Physician Brochure

Proven Clinical Results of the UroLift® System

Faster Recovery. Minimal Risks. Proven Outcomes.

The UroLift® System has demonstrated a symptom relief better than reported for medications.2,3 The UroLift® System treatment preserves sexual function*2,3,4 with low rates of complications.3

  • Rapid symptom relief and recovery3,4

  • Low catheter rate1,3,5-8

  • Highly durable1

What Comprises the UroLift® System?

The UroLift® System is comprised of two main components.

UroLift® Delivery Device

It is inserted transurethrally through a rigid sheath under cystoscopic visualisation to reach the targeted area of obstruction. Each delivery device contains one UroLift® Implant.

UroLift® Implant

The obstructing prostatic lobes are held apart by small permanent UroLift® Implants that are deployed by the delivery device.

* Typically, four implants are placed into the prostate.
Download Product Info

MRI Information

The UroLift® Implant is MR Conditional.
View Instructions for Use

A patient with this device can be safely scanned in an MR system immediately after placement meeting the following conditions:

  • Static magnetic field of 3.0 Tesla or less
  • Maximum spatial field gradient of 720 Gauss/cm (15 T/m) (extrapolated)
  • Maximum MR system reported, whole-body averaged specific absorption rate (SAR) of 4W/kg for 15 minutes of scanning (i.e. per pulse sequence) (First Level Controlled Operating Mode)

Under the scan conditions defined above, the UroLift® Implant is expected to produce a maximum temperature rise of 2.4°C after 15 minutes of continuous scanning (i.e. per pulse sequence).

The safety of the delivery system has not been evaluated in the MR environment, and therefore, the delivery system should not be used within the MR environment.

Patient implant cards are provided to inform the patient that the UroLift® Implant is MR Conditional and can safely be scanned only under specific MR conditions.

Read More

*No instances of new onset, sustained erectile or ejaculatory dysfunction in the LIFT pivotal study
이 제품은 '의료기기'이며, '사용상의 주의사항'과 '사용방법'을 잘 읽고 사용하십시오.
이식형결찰사 / 50대 이상 남성의 비대해진 전립선조직을 묶어 방광출구(요도)폐색을 치료하는 이식형제품

References

1.

Roehrborn et al. Can J Urol 2017

2.

AUA Guidelines 2003, 2020

3.

Roehrborn, J Urology 2013

4.

McVary, J Urol 2016

5.

Shore, Can J Urol 2014

6.

Bachmann, Eur Urol 2014 May

7.

Mollengarden, Prostate Cancer Prostatic Dis 2018

8.

Gilling, J Urol 2017

9.

EAU Guidelines 2022

Healthcare Professional Confirmation

The information on the page you are about to enter is intended for Healthcare Professionals only.
By clicking the box below, you confirm that you are a Healthcare Professional.

Continue